Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Down 51.0% in November

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 38,100 shares, a drop of 51.0% from the October 31st total of 77,800 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 0.0 days.

Bio-Path Stock Performance

NASDAQ:BPTH remained flat at $0.77 during mid-day trading on Friday. 21,582 shares of the company’s stock traded hands, compared to its average volume of 1,097,792. The business has a 50-day simple moving average of $0.95 and a 200 day simple moving average of $1.47. Bio-Path has a 52-week low of $0.61 and a 52-week high of $12.37.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Bio-Path in a research note on Sunday, November 24th. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. Institutional investors and hedge funds own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.